The rare kidney cancer nephroblastoma, sometimes called wilms' tumor, typically affects young people. Children with nephroblastoma are most frequently affected between the ages of 3 and 4, cases after age 5 are substantially less prevalent. Although it can occasionally be seen in both kidneys at the same time, nephroblastoma typically only affects one kidney. When cells experience DNA errors, cancer develops. The errors cause the cells to grow and divide uncontrollably. The accumulating cells then form a tumor. This process takes place in the kidney cells in nephroblastoma.
Global nephroblastoma treatment market is estimated to be valued at US$ 1,653.0 million in 2022 and is expected to exhibit a CAGR of 4.6% during the forecast period (2022-2030).
Figure 1.Global Nephroblastoma Treatment Market Share (%), by Type, 2022
Increasing approvals from regulatory bodies to key players for nephroblastoma treatment in market are expected to drive growth of the nephroblastoma treatment market.
Key players in market are focused on receiving approvals from regulatory bodies for drugs used to treat nephroblastoma, which is expected to drive the market growth over the forecast period. For instance, in May 2022, Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had accepted the company's Investigational New Drug (IND) application for the evaluation of CUE-102, its second interleukin 2 (IL-2)-based CUE-100 series biologic, in a dose escalation and expansion monotherapy Phase 1 trial, which would have a starting dose of 1 mg/kg for the treatment of wilms’ tumor 1 (WT1)-positive recurrent/metastatic cancers, with initial focus on gastric, pancreatic, ovarian and colon cancers.
|Base Year:||2021||Market Size in 2022:||US$ 1,653.0 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||4.6%||2030 Value Projection:||US$ 2,366.5 Mn|
Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals
|Restraints & Challenges:||
Figure 2.Global Nephroblastoma Treatment Market Share (%), by Distribution Channel, 2022
Rising research and development activities by key players for the treatment of nephroblastoma are expected to drive the market growth during the forecast period.
Key players in market are focused on carrying out research and development activities for the development of drugs used to treat nephroblastoma, which is expected to drive the market growth over the forecast period. For instance, the Children's Oncology Group, a clinical trials group supported by the National Cancer Institute, is currently studying the effect of combination chemotherapy and surgery in treating young patients with wilms tumor. As of August 4, 2022, the study is currently in phase 3 of its clinical trial and the study is expected to be completed by November 2023.
Global Nephroblastoma Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.
COVID-19 can affect the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, UAE, Egypt, and others, are facing problems with regards to the transportation of products from one place to another.
The COVID-19 pandemic had a negative economic impact on the global nephroblastoma treatment market, owing to the delay in routine screening of cancer. For instance, according to an article published by the National Center for Biotechnology Information, in September 2021, on March 16, 2020, the U.K., postponed routine screening for cancer in response to the COVID-19 pandemic.
Global Nephroblastoma Treatment Market: Restraint
The major factor that hinders growth of the global nephroblastoma treatment market includes high treatment cost of nephroblastoma. For instance, according to an article published by the American Society of Clinical Oncology, in November 2018, the cost for a full course of treatment and follow-up was determined to be between US$ 1,490 and US$ 2,093 for a patient with nephroblastoma according to the study at the Butaro Cancer Center of Excellence (BCCOE), located at the Butaro District Hospital in rural northern Rwanda, Central Africa.
Major players operating in the global nephroblastoma treatment market include Merck & Co., Inc., Recordati Rare Diseases, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Cipla Inc., Actiza Pharmaceutical Private Limited, Teva Pharmaceutical Industries Ltd., Alvogen, Accord Healthcare Ireland Ltd., Baxter, Amneal Pharmaceuticals LLC., Cadila Pharmaceuticals Ltd., and Xediton Pharmaceuticals.
Nephroblastoma, also known as Wilms tumor, is the most prevalent kind of renal cancer among pediatrics. Although the exact cause of Wilms tumor is unknown, genetic changes related to the normal embryological development of the genitourinary tract are thought to be to the reason behind the tumor. The most typical childhood abdominal cancer, wilms tumor, often manifests between the ages of 3 and 5. Nephrectomy and systemic chemotherapy are typically used to treat wilms tumors, while some regimens start the chemotherapy first and perform the nephrectomy afterwards. Vincristine and dactinomycin are most frequently used in the initial chemotherapy. Carboplatin, cyclophosphamide, etoposide, and doxorubici are also used. Some common symptoms of wilms tumor include belly pain, swelling in the belly, fever, nausea, lack of appetite, constipation, and shortness of breath. There are two kinds of wilms tumors, favorable histology and unfavorable or anaplastic histology.
Increasing research and development activities by various organizations and researchers to develop treatment options for nephroblastoma are expected to drive the market growth over the forecast period. For instance, according to the findings of the study published in the Journal of Clinical Oncology in September 2021, the COSMIC-021 study (NCT03170960), a multicenter, phase 1b, open-label study, the combination of cabozantinib plus atezolizumab demonstrated encouraging clinical activity in patients with advanced renal cell carcinoma (RCC). Robust clinical activity was observed across dose levels and histologic subtypes. The safety profile with the combination was tolerable with dose modification and comparable to previous reports. The findings of the study were published by Sumanta K. Pal, MD, Clinical Professor, Department of Medical Oncology & Therapeutics Research, Co-director, Kidney Cancer Program, City of Hope Comprehensive Cancer Center in Duarte, CA, U.S.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.